Skip to main content
ClinicalTrials.govrestricted

This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-def

ClinicalTrials.gov study NCT07321860. IPD Sharing: Not stated. Countries: 0. Publications: 0.

ShareScore

20/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
8
Harmonization
8
Access
0
Reuse readiness
0
Engagement
4

Topics

Dataset details

Repository
ClinicalTrials.gov
Published
February 11, 2026
License
IPD-UNDECIDED
DOI
clinicaltrials.gov/NCT07321860

Scored with release 0.9.0

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.